SynthesisAnnals of the rheumatic diseases2022

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.

Peter C Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.